Double-stranded RNA targeting cdk5 and use thereof
Double-stranded RNA targeting CDK5 is developed to address the limitations of current treatments by enhancing RNAi and stability, effectively inhibiting CDK5 expression and cell proliferation for neurodegenerative diseases and cancer.
Patent Information
- Application Number
- PCT/JP2026/017309
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-01
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as cancer, lack effective methods to target CDK5, a kinase involved in these conditions, and existing CDK5 inhibitors have limitations in efficacy and specificity.
Development of double-stranded RNA (dsRNA) specifically designed to target CDK5, with optimized sequences and additional nucleotide pairs to enhance stability and induce RNA interference (RNAi), capable of suppressing CDK5 expression and cell proliferation.
The dsRNA effectively inhibits CDK5 expression and cell proliferation, offering potential therapeutic benefits for neurodegenerative diseases and cancer by enhancing RNAi and improving stability within cells.
Smart Images

Figure JP2026017309_12112026_PF_FP_ABST
Abstract
Description
Double-stranded RNA targeting CDK5 and use thereof
[0001] The present disclosure relates to a double-stranded RNA targeting CDK5 (cyclin dependent kinase 5) and use thereof. This application claims priority based on Japanese Patent Application No. 2025-077204 filed on May 7, 2025, the entire content of which is incorporated herein by reference.
[0002] CDK5 is a serine / threonine kinase that is important for neuronal development, synaptic plasticity, neurotransmission and the like. CDK5 is known to be potentially involved in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. CDK5 is also known to be potentially associated with cancer. For example, Japanese Patent Laid-Open No. 2023-015314 states that CDK5 inhibitors can suppress brain metastasis of several types of cancer.
[0003] Japanese Patent Laid-Open No. 2023-015314
[0004] By the way, the present inventor is advancing the development of double-stranded RNA targeting CDK5 in order to provide a novel nucleic acid medicament that can be used for the treatment of at least one type of disease. The present inventor intends to provide a particularly highly effective double-stranded RNA among the double-stranded RNAs targeting CDK5.
[0005] As one aspect of the present technology, a double-stranded RNA targeting CDK5 is provided. In some embodiments, the double-stranded RNA includes a first strand containing a main sequence, and a second strand containing a complementary sequence that complementarily binds to the main sequence. The main sequence consists of any one of the following base sequences: CAUUCCUCUUCCAGCUACU (SEQ ID NO: 1); CCUCUUCCAGCUACUAAAA (SEQ ID NO: 2); GGGCUGGGAUCUGUCAUA (SEQ ID NO: 3); and GGUCAGCCGGCUGCAUCUU (SEQ ID NO: 4).
[0006] The double-stranded RNA exhibits excellent effects as a double-stranded RNA targeting CDK5.
[0007] In some embodiments, the first strand includes a first additional sequence consisting of one to four base pairs attached to the 5' and / or 3' ends of the main sequence, and the second strand includes a second additional sequence consisting of one to four base pairs attached to the 5' and / or 3' ends of the complementary sequence. With such a configuration, RNA interference (RNAi) is more easily induced.
[0008] In some embodiments, the base sequence constituting the first additional sequence is thymine-thymine (TT). This can improve the stability of double-stranded RNA within cells.
[0009] In some embodiments, the base sequence constituting the second additional sequence is thymine-thymine (TT). This can improve the stability of double-stranded RNA within cells.
[0010] In some embodiments, the first strand and / or the second strand include nucleotide analogs. This can improve the stability of the double-stranded RNA.
[0011] In some embodiments, the base sequence constituting the first strand is 19 to 27 bases, and the base sequence constituting the second strand is 19 to 27 bases. With such a configuration, RNAi is more easily induced.
[0012] In one aspect of this technology, a composition comprising the double-stranded RNA disclosed herein is provided. The double-stranded RNA disclosed herein can be used as a component of the composition. Because this composition contains the double-stranded RNA disclosed herein, it can suppress the proliferation of at least one type of cell.
[0013] Furthermore, in one aspect of this technology, a method for suppressing the proliferation of at least one type of cell is provided. This method includes the steps of preparing a composition disclosed herein and providing the composition to the cells.
[0014] Figure 1 is a graph showing the cell viability rate for each example.
[0015] <Definition of Terms> Matters other than those specifically mentioned herein (e.g., the structure of double-stranded RNA) that are necessary for carrying out this technology (e.g., general matters such as methods for synthesizing polynucleotides, cell culture techniques, methods for preparing compositions, etc.) can be understood as design matters of those skilled in the art based on prior art in fields such as cell engineering, physiology, medicine, pharmacy, organic chemistry, biochemistry, genetic engineering, protein engineering, molecular biology, and genetics. The technology disclosed herein can be carried out based on the contents disclosed herein and common technical knowledge in the relevant art.
[0016] In this specification, "polynucleotide" refers to a polymer in which multiple (two or more) nucleotides are linked by phosphodiester bonds, and is not limited by the number of nucleotides. For example, a polymer containing both deoxyribonucleotides and ribonucleotides as nucleotides is also included in the definition of "polynucleotide" in this specification. Furthermore, in this specification, "artificially designed polynucleotide" refers to a polynucleotide whose nucleotide chain (total length) does not exist naturally on its own, but is artificially synthesized by chemical synthesis or biosynthesis (i.e., production based on genetic engineering).
[0017] In this specification, "first chain" and "second chain" refer to a sense chain (which may also be called a coded chain or passenger chain) and an antisense chain (which may also be called a template chain, non-coded chain, or guide chain). That is, if the first chain is a sense chain, the second chain is an antisense chain. Also, if the second chain is a sense chain, the first chain is an antisense chain.
[0018] In this specification, unless otherwise indicated by "5'" and "3'", the left side of a nucleotide sequence is always the 5' end and the right side is always the 3' end. Furthermore, in this specification, "amino acid residue" refers to the N-terminal and C-terminal amino acids of a peptide chain, unless otherwise specified. Also, in amino acid sequences described in this specification, the left side is always the N-terminus and the right side is always the C-terminus.
[0019] In this specification, "tumor" is a broad term encompassing carcinomas, sarcomas, and lesions of the blood and hematopoietic tissue (such as leukemia and lymphoma), including tumors in general (typically malignant tumors). "Tumor cell" is synonymous with "cancer cell," referring to cells that form such tumors, typically those that have abnormally proliferated independently of surrounding normal tissue (so-called cancerous cells). Therefore, unless otherwise specified, any cell classified as a tumor cell (cancer cell) rather than a normal cell is referred to as a tumor cell, regardless of its origin or characteristics.
[0020] In this specification, when a numerical range is described as "A to B (where A and B are arbitrary numbers)," it means "A or greater and B or less," and also encompasses the meanings of "greater than A and less than B," "greater than A and less than or equal to B," and "A or greater and less than B."
[0021] <Double-stranded RNA> The double-stranded RNA disclosed herein comprises a first strand and a second strand. In some embodiments, the first strand comprises a main sequence and a first addition sequence, and the second strand comprises a complementary sequence that binds complementaryly to the main sequence of the first strand and a second addition sequence. The first and second strands are hybridized in the main sequence and the complementary sequence. The first and second strands may be artificially synthesized polynucleotides. In some embodiments, the first and second addition sequences may be omitted.
[0022] The double-stranded RNA disclosed herein can function as a CDK5-targeting siRNA (small interfering RNA). In other words, the double-stranded RNA disclosed herein can suppress the gene expression of CDK5. That is, the double-stranded RNA disclosed herein can induce RNA interference (RNAi). RNAi is a gene silencing process that suppresses gene expression in a sequence-specific manner using short double-stranded RNA such as siRNA. Although not limited to the following mechanism, when siRNA is introduced into a cell, it forms a complex called RISC (RNA-induced silencing complex) with intracellular proteins. RISC binds to a homologous sequence of RNA (e.g., mRNA) that has the base sequence encoding the target protein (here, CDK5). Subsequently, RISC can specifically cleave the RNA (e.g., mRNA). This inhibits the translation of the target protein.
[0023] The double-stranded RNA disclosed herein exhibits excellent function as a double-stranded RNA targeting CDK5. For example, introduction of the disclosed double-stranded RNA into cells can suppress the proliferation of at least one type of cell. Cell proliferation inhibition is known as one of the effects of double-stranded RNAs targeting CDK5 (e.g., siRNA, etc.). Therefore, it is presumed that double-stranded RNAs with high cell proliferation inhibition effects will exhibit excellent effects as double-stranded RNAs targeting CDK5. The disclosed double-stranded RNA can be used, for example, as a cell proliferation inhibitor (e.g., an antitumor agent). Furthermore, since the disclosed double-stranded RNA can suppress CDK5 expression, it can be used as a therapeutic agent (nucleic acid drug) for diseases that may be associated with CDK5. Examples of diseases that may be associated with CDK5 include neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. In this specification, "therapeutic agent" includes drugs intended to reduce, improve, or cure the symptoms of a disease, as well as drugs intended to prevent or prevent the recurrence of a disease.
[0024] Information on CDK5 mRNA can be obtained from international databases. Examples of such international databases include NCBI (National Center for Biotechnology Information), ENA (European Nucleotide Archive), DDBJ (DNA Data Bank of Japan), UniPlot, and Ensemble. For example, two transcript variants of human CDK5 mRNA are known. The nucleotide sequence information for human CDK5 transcript variant 1 mRNA is available in NCBI under accession number NM_004935.4. The nucleotide sequence of human CDK5 transcript variant 1 mRNA is shown in Sequence ID 9. The mRNA sequence information for human CDK5 transcript variant 2 is available in NCBI under accession number NM_001164410.3. The mRNA sequence for human CDK5 transcript variant 1 is shown in Sequence ID No. 10.
[0025] <First Strand> The main sequence of the first strand may consist of polynucleotides, which are polymers of ribonucleotides. In other words, the main sequence may consist of RNA. That is, the base sequence of the main sequence is typically represented by four letters: A (adenine), U (uracil), G (guanine), C (cytosine), or a, u, g, c. However, in the attached sequence listing, uracil may be represented by T (thymine).
[0026] The main sequence contains a portion of the nucleotide sequence that constitutes the CDK5 mRNA (transcript variant 1 or 2). In some preferred embodiments, the main sequence consists of a portion of the nucleotide sequence that constitutes the CDK5 mRNA (transcript variant 1 or 2).
[0027] The number of nucleotides (bases) constituting the main sequence may be, for example, 19 or more and 23 or 19 or more and 21 or less. Alternatively, the number of nucleotides constituting the main sequence may be 19.
[0028] In some embodiments, the 5' end of the main sequence is guanine (G) or cytosine (C). Because guanine and cytosine have a higher binding affinity to the complementary strand than adenine and uracil, the stability of the 5' end of the first strand (i.e., the 3' end of the second strand) is increased. In other words, the stability of the 5' end of the second strand is relatively lower. Although the details of the mechanism are not clear, RISC, an RNAi-related protein, tends to preferentially incorporate the strand whose 5' end is more energetically unstable than the sense strand or antisense strand. Therefore, having guanine or cytosine at the 5' end of the main sequence makes it easier for the antisense strand (in this case, the second strand) to be incorporated into RISC, thus more favorably inducing RNAi. This allows double-stranded RNA to function favorably as siRNA.
[0029] In some embodiments, at least two of the five bases at the 3' end of the main sequence are adenine or uracil, preferably three or more bases are adenine or uracil. This results in the 5' end of the second strand being relatively less stable than the 3' end. Consequently, the second strand is more readily incorporated into RISC, allowing for more favorable induction of RNAi.
[0030] The total GC content of the main sequence (the total percentage of G and C in the entire base sequence constituting the main sequence) is not particularly limited, but is preferably between 40% and 65%, and more preferably between 45% and 55%. The GC content is a parameter related to the binding strength between the antisense strand incorporated into the RISC and the RNA having the main sequence, as well as the ease of RNA cleavage. With the above GC content, the effects of RNAi can be efficiently exerted.
[0031] Preferred main sequences include the following nucleotide sequences: CAUUCCUCUUCCAGCUACU (Sequence ID 1); CCUCUUCCAGCUACUAAA (Sequence ID 2); GGGCUGGGAAUUCUGUCAUA (Sequence ID 3); GGUCAGCCGGGCUGCAUCUU (Sequence ID 4); CUAAAGGGGCUGGGAAUUCU (Sequence ID 5); GUCAUAGCCGCCAAUGUGCU (Sequence ID 6); GUCAGCCGGCUGCCAAUCUUU (Sequence ID 7); and CCGGCUGCCAAUCUUUGCAGA (Sequence ID 8). Among these, double-stranded RNA having the nucleotide sequence shown in any of Sequence IDs 1 to 4 as the main sequence is preferred. Furthermore, double-stranded RNA having the nucleotide sequence shown in SEQ ID NO: 1 or 3 as its main sequence is particularly preferred. Double-stranded RNA having the nucleotide sequence shown in any of SEQ ID NOs: 1 to 4 as its main sequence is particularly excellent in function as a double-stranded RNA targeting CDK5, and can, for example, significantly suppress cell proliferation.
[0032] The nucleotide sequences shown in SEQ ID NOs: 1-8 are all included as part of the mRNA sequence of human CDK5 transcript variant 1. On the other hand, the mRNA sequence of human CDK5 transcript variant 2 includes the nucleotide sequences shown in SEQ ID NOs: 4, 7, and 8, but does not include the nucleotide sequences shown in SEQ ID NOs: 1-3 and 5-6. Therefore, double-stranded RNA having any of the nucleotide sequences shown in SEQ ID NOs: 1-3 or 5-6 may be able to specifically repress the expression of human CDK5 transcript variant 1 mRNA. Furthermore, double-stranded RNA having any of the nucleotide sequences shown in SEQ ID NOs: 4, 7, or 8 may be able to repress the expression of human CDK5 transcript variants 1 and 2.
[0033] Within the scope of achieving the effects of this technology, the main sequence may be a modified sequence. For example, the main sequence (for example, the nucleotide sequence shown in any of SEQ ID NOs: 1 to 8) may have one or more nucleotides (for example, two nucleotides) that differ from a part of the nucleotide sequence constituting CDK5 mRNA. Alternatively, the main sequence (for example, the nucleotide sequence shown in any of SEQ ID NOs: 1 to 8) may consist of a nucleotide sequence in which one or more nucleotides (for example, two nucleotides) are deleted and / or added (inserted) from a part of the nucleotide sequence constituting CDK5 mRNA. Furthermore, the main sequence (for example, the nucleotide sequence shown in any of SEQ ID NOs: 1 to 8) may be a nucleotide analog such as a modified ribonucleotide.
[0034] In this specification, "achieving the effects of this technology" means, for example, that when the effect of double-stranded RNA consisting of the base sequence before modification (for example, the base sequence shown in any of SEQ ID NOs: 1 to 8) is taken as 100%, the effect of double-stranded RNA consisting of the modified base sequence is at least 80%, preferably at least 90%, and more preferably at least 100%.
[0035] The nucleotide sequences shown in Sequence IDs 1 to 8 can be conserved in the CDK5 genes of non-human organisms (e.g., primates such as gorillas and bonobos). Therefore, the organism from which CDK5 originates is not limited to humans in this specification. For example, the aforementioned international database can be used to confirm whether the nucleotide sequences shown in Sequence IDs 1 to 8 may be present in the nucleotide sequences of CDK5 genes of non-human organisms.
[0036] The first strand may include a first addition sequence that is attached to the 5' and / or 3' ends of the main sequence. Preferably, the first addition sequence is attached to the 3' end of the main sequence. The addition of the first addition sequence to the main sequence can more effectively induce RNAi.
[0037] The first addition sequence may consist of nucleotides or polynucleotides (dimers, trimers, or tetramers). The polynucleotides constituting the first addition sequence may consist of ribonucleotides only, deoxyribonucleotides only, or both ribonucleotides and deoxyribonucleotides. That is, the first strand may be entirely RNA, or it may be a chimeric polynucleotide of RNA and DNA.
[0038] The first addition sequence is composed of, for example, a nucleotide sequence of 1 to 4 nucleotides, preferably a nucleotide sequence of 2 to 4 nucleotides, and more preferably a nucleotide sequence of 2 nucleotides. The nucleotide sequence constituting the first addition sequence preferably contains adenine, uracil, or thymine. From the viewpoint of improving the stability of double-stranded RNA, the nucleotide sequence constituting the first addition sequence is preferably TT (thymine-thymine). The first addition sequence may protrude from the 5' or 3' end of the second strand. In some examples, the first addition sequence may be an overhang in the siRNA. When the first addition sequence is added to both the 5' and 3' ends of the main sequence, the total number of nucleotides may be, for example, 2 to 4 nucleotides.
[0039] The first strand is composed of, for example, a base sequence of 21 to 27 bases, and may consist of 21 to 25 bases, or 21 to 23 bases. In a preferred embodiment, the base sequence of the first strand consists of 21 to 23 bases, comprising a main sequence of 19 to 21 bases and a first additional sequence of 2 bases. In such an embodiment, RNAi can be effectively induced.
[0040] The first strand may contain modified RNA or nucleotide analogs such as DNA, etc., as long as the effects of the present technology are achieved. Examples of the type of modification include methylation, pseudouridylation, fluorination, deamination, and the like. Examples of the nucleotide analog include pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-fluorouracil, inosine, acyclic artificial nucleic acids, and the like. For example, one or more (for example, 2 to 5) of the nucleotides constituting the first strand may be substituted with nucleotide analogs.
[0041] <Second Strand> The complementary sequence of the second strand has a base sequence that complementarily binds to the main sequence of the first strand. As a result, the first strand and the second strand hybridize to form a double-stranded structure. The complementary sequence may be composed of a polynucleotide that is a polymer of ribonucleotides. In other words, the complementary sequence may be composed of RNA.
[0042] Note that, in the present specification, "complementarily binds" typically means forming a base pair in which adenine and uracil or thymine are linked by hydrogen bonds, and / or forming a base pair in which guanine and cytosine are linked by hydrogen bonds. However, in the case of modified bases, it may also include cases where base pairs can be formed with other bases via hydrogen bonds.
[0043] The complementary sequence preferably has a base sequence complementary to the entire main sequence. That is, it is preferable that each of the bases constituting the main sequence forms a base pair with a base contained in the complementary sequence. As a result, a stable double-stranded structure in which each base is complementarily bound is formed, which may facilitate the induction of RNAi.
[0044] As long as the effects of the present technology are achieved, the complementary sequence may partially complementarily bind to the bases constituting the main sequence. That is, the complementary sequence does not need to form base pairs with some of the bases constituting the main sequence. For example, the complementary sequence may not form base pairs with one or more (for example, 2 bases) of the bases constituting the main sequence.
[0045] The number of nucleotides constituting the complementary sequence may be, for example, the same as the number of nucleotides constituting the main sequence. In a preferred embodiment, the number of nucleotides in the complementary sequence is the same as that in the main sequence, and all nucleotides constituting the main sequence and all nucleotides constituting the complementary sequence are complementarily bound. Thereby, a stable double-stranded structure is formed, which can facilitate the induction of RNAi.
[0046] As long as the effects of the present technology are achieved, the number of nucleotides constituting the complementary sequence may be greater than the number of nucleotides constituting the main sequence. For example, the 5'-terminal side of the complementary sequence may have one or more (for example, 2 or more and 4 or less) nucleotides that do not form base pairs with the main sequence. Further, for example, one or more (for example, 2 or more and 4 or less, such as a loop structure) nucleotides that do not form base pairs with the bases of the main sequence may be arranged between the sequences of the complementary sequence that complementarily bind to the main sequence.
[0047] As long as the effects of the present technology are achieved, the number of nucleotides constituting the complementary sequence may be less than the number of nucleotides constituting the main sequence. For example, the number of nucleotides constituting the complementary sequence may be 1 or 2 less than the number of nucleotides constituting the main sequence.
[0048] The second strand may include a second additional sequence added to the 5'-terminal side and / or 3'-terminal side of the complementary sequence. From the viewpoint of improving the function as siRNA, when the first additional sequence is added to the 3'-terminal side of the main sequence in the first strand, the second additional sequence is preferably added to the 3'-terminal side of the complementary sequence.
[0049] The second additional sequence may be composed of nucleotides or polynucleotides (dimers, trimers, or tetramers). The polynucleotide constituting the second additional sequence may be composed of only ribonucleotides, only deoxyribonucleotides, or may comprise both ribonucleotides and deoxyribonucleotides. That is, the entire second strand may be RNA, or may be a chimeric polynucleotide of RNA and DNA.
[0050] The second addition sequence is, for example, composed of a nucleotide sequence of 1 to 4 nucleotides, preferably a nucleotide sequence of 2 to 4 nucleotides, and more preferably a nucleotide sequence of 2 nucleotides. The second addition sequence preferably contains adenine, uracil, or thymine. From the viewpoint of improving the stability of double-stranded RNA, the nucleotide sequence constituting the second addition sequence is preferably TT (thymine-thymine). The second addition sequence may protrude from the 5' or 3' end of the first strand. In some examples, the second addition sequence may be an overhang in the siRNA. When the second addition sequence is added to both the 5' and 3' ends of the main sequence, the total number of nucleotides is preferably, for example, 2 to 4 nucleotides.
[0051] While not particularly limited, the base sequence of the second strand may consist of, for example, 21 to 27 bases, 21 to 25 bases, or 21 to 23 bases. In a preferred embodiment, the base sequence of the second strand consists of a 21 to 23 base sequence comprising 19 to 21 bases of the complementary sequence and 2 bases of the second addition sequence. In such an embodiment, RNAi can be effectively induced.
[0052] The second strand may contain modified RNA or DNA or other nucleotide analogs, insofar as the effects of this technology are achieved. The types of modifications and examples of nucleotide analogs may be the same as those for the first strand described above. For example, one or more (e.g., 2 to 5) of the nucleotides constituting the second strand may be replaced with nucleotide analogs.
[0053] In some embodiments, the first and / or second strands of the double-stranded RNA disclosed herein may contain nucleotide analogs. For example, the first and / or second strands may contain acyclic artificial nucleic acids as nucleotide analogs. For example, in some embodiments, the first strand includes a first additional sequence (hereinafter also referred to as the "third additional sequence") consisting of one or two nucleotide sequences at the 5' and 3' ends of the main sequence, respectively, and the second strand includes a second additional sequence (hereinafter also referred to as the "fourth additional sequence") consisting of one or two nucleotide sequences at the 5' and 3' ends of the complementary sequence, respectively. In some embodiments, the fourth additional sequence has a nucleotide sequence complementary to the third additional sequence. That is, each of the nucleotides constituting the fourth additional sequence forms a base pair with a nucleotide contained in the third additional sequence. This allows the third and fourth additional sequences to hybridize.
[0054] The third addition sequence of the first strand may be composed of an acyclic artificial nucleic acid. An acyclic artificial nucleic acid refers to an artificial nucleic acid in which the main chain structure of a natural nucleic acid has been modified into an acyclic skeleton. Known acyclic artificial nucleic acids can be used. For example, refer to Japanese Patent Application Publication No. 2016-130232. Examples of acyclic artificial nucleic acids include SNA (Serinol Nucleic Acid), L-aTNA (L-acyclic Threoninol Nucleic Acid), and D-aTNA (D-acyclic Threoninol Nucleic Acid). From the viewpoint of double-stranded RNA stability, it is preferable that the third addition sequence is composed of SNA or L-aTNA. The structures of SNA and L-aTNA are shown in the following formulas (1) and (2), respectively.
[0055]
[0056] In formula (1) above, Base is a base that makes up nucleic acid, and may be, for example, adenine (A), guanine (G), cytosine (C), uracil (U), thymine (T), etc. Also, in formula (1), the (S) end may correspond to the 5' end in DNA or RNA, and the (R) end may correspond to the 3' end in DNA or RNA.
[0057]
[0058] In formula (2) above, Base is a base that makes up nucleic acid, and may be, for example, adenine (A), guanine (G), cytosine (C), uracil (U), thymine (T), etc. Also, in formula (2), the 1' side may correspond to the 3' side in DNA or RNA. Also, the 3' side may correspond to the 5' side in DNA or RNA.
[0059] The base sequence of the first strand, which consists of a main sequence and a third addition sequence containing an acyclic artificial nucleic acid, preferably matches a portion of the base sequence encoding CDK5. In this case, if the third addition sequence contains uracil, it is preferable that the uracil in the third addition sequence is replaced with thymine.
[0060] The fourth addition sequence at the 3' end of the complementary sequence of the second strand may be composed of an acyclic artificial nucleic acid. Known acyclic artificial nucleic acids can be used. Examples of acyclic artificial nucleic acids include SNA, L-aTNA, and D-aTNA. From the viewpoint of double-stranded RNA stability, it is preferable that the fourth addition sequence at the 3' end of the complementary sequence is composed of SNA or L-aTNA. If the third addition sequence contains adenine, it is preferable that the base of the fourth addition sequence at a complementary position is thymine.
[0061] Furthermore, double-stranded RNA, including acyclic artificial nucleic acids, can be manufactured according to known synthesis methods. For example, it can be manufactured by referring to Japanese Patent Application Publication No. 2016-130232.
[0062] In some embodiments, the first and / or second chains may have ligands that bind to receptors specifically expressed in the target cells. The ligands may, for example, be attached to the 5' and / or 3' ends of the first chain. The ligands may be, for example, N-acetylgalactosamine (GalNAc) or derivatives thereof. Having GalNAc as a ligand may improve delivery to hepatocytes.
[0063] <Method for Producing Double-Stranded RNA> The first and second strands constituting the double-stranded RNA disclosed herein can be produced according to general chemical synthesis methods. For example, they can be synthesized using a commercially available automated DNA / RNA synthesizer. Alternatively, the first and second strands may be synthesized in vitro or in vivo based on genetic engineering techniques. It is preferable that the synthesized first and second strands be purified, which can be done, for example, by HPLC.
[0064] The double-stranded RNA disclosed herein can be produced, for example, by annealing (hybridizing) the first and second strands. The annealing method can be any conventionally known method. For example, the first and second strands can be mixed in equal amounts in a solvent, heated at 90°C for 1 to 5 minutes, and then cooled to 4°C to room temperature to perform annealing. Suitable solvents include, for example, distilled water, pure water, ultrapure water, and buffers (e.g., HEPES-KOH buffer with pH 7.4, PBS, etc.). To prevent contamination of the solvent with active RNase (RNA-degrading enzyme), it is preferable to use a solvent that has been treated, for example, by DEPC treatment or autoclaving.
[0065] <Other Embodiments of Double-Stranded RNA> The double-stranded RNA disclosed herein may include a form in which the first strand and the second strand are partially double-stranded via a loop structure. That is, double-stranded RNA can also be used as shRNA (short hairpin RNA) in another embodiment. ShRNA is RNA in which a main sequence, its complementary sequence, and a loop sequence for forming the loop structure are present on a single strand. Due to the presence of the loop structure, the main sequence and its complementary sequence hybridize, forming a partially double-stranded structure. As a result, the shRNA can be processed by the intracellular enzyme Dicer, and the double-stranded RNA described above can be formed.
[0066] The structure of the shRNA may be the same as that of conventionally known shRNAs. The length of the base sequence constituting the shRNA may be, for example, 50 to 80 bases. The length of the base sequence constituting the loop sequence may be, for example, 19 to 29 bases. The shRNA can be incorporated into a vector (e.g., a lentiviral expression vector). By using the shRNA, RNAi can be stably induced.
[0067] <Composition> The composition disclosed herein contains the double-stranded RNA described above. In addition to the double-stranded RNA described above, the composition may also contain various pharmaceutically acceptable carriers depending on the form of use. Preferred carriers include, for example, carriers commonly used in pharmaceuticals as diluents, excipients, etc. Such carriers vary appropriately depending on the use and form of the composition. Typically, these include water, physiological buffers, various organic solvents, etc. Such carriers may also be aqueous solutions of alcohol (ethanol, etc.) of appropriate concentration, glycerol, non-drying oils such as olive oil, lipid nanoparticles (LNPs), or liposomes, etc. Such carriers may also be transfection reagents (e.g., cationic molecules) or other reagents used for cell introduction. By-components that may be included in the pharmaceutical composition include various fillers, bulking agents, binders, humectants, surfactants, dyes, fragrances, etc. It may also include carriers used in conventionally known drug delivery systems (DDS).
[0068] The form of the composition disclosed herein is not particularly limited. For example, typical forms of the composition include liquids, suspensions, emulsions, aerosols, foams, granules, powders, tablets, capsules, and ointments. It can also be prepared as a lyophilized product or granules for use by injection, etc., by dissolving it in physiological saline or a suitable buffer (e.g., PBS) immediately before use to prepare a drug solution. Furthermore, the process of preparing various forms of drugs (compositions) using double-stranded RNA (main component) and various carriers (sub-components) as materials can be based on conventionally known methods, and such formulation methods themselves do not characterize this disclosure, so a detailed explanation is omitted. For detailed information on formulations, see, for example, Comprehensive Medicinal Chemistry, edited by Corwin Hansch, published by Pergamon Press (1990).
[0069] The composition disclosed herein contains the CDK5-targeting double-stranded RNA described above. Therefore, the composition exhibits the function of the CDK5-targeting double-stranded RNA at an excellent level. One example of the function of the CDK5-targeting double-stranded RNA is its ability to inhibit cell proliferation. Therefore, the composition can, for example, inhibit the proliferation of at least one type of cell. The cells to which the double-stranded RNA is introduced are, for example, cells that express CDK5 mRNA. The CDK5 mRNA preferably has the same base sequence as the main sequence of the double-stranded RNA contained in the composition. CDK5 mRNA is expressed in many tissues of the body, although the expression levels vary. Therefore, the double-stranded RNA disclosed herein can inhibit the cell proliferation of body tissues or cells derived from body tissues that express CDK5 mRNA. Examples of body tissues that express CDK5 mRNA include the brain, eyes, endocrine tissue, lungs, liver, gallbladder, kidneys, pancreas, urinary tract, uterus, muscle tissue, adipose tissue, skin, bone marrow, lymphoid tissue, etc. Furthermore, examples of cells expressing CDK5 mRNA include tumor cells. Examples of tumor cells include adrenocortical carcinoma, cholangiocarcinoma, bladder cancer, bone tumors, brain tumors, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, lymphoma, myeloma, neuroblastoma, uterine fibroids, ovarian cancer, pancreatic cancer, prostate cancer, rhabdoid tumors, sarcomas, skin cancer, testicular tumors, and thyroid cancer. The compositions of this disclosure can, for example, suppress the proliferation of tumor cells. Therefore, the double-stranded RNA and compositions of this disclosure can be suitably used, for example, as antitumor agents (anticancer agents) that suppress the proliferation of tumor cells.
[0070] In some embodiments, the composition includes, in addition to the double-stranded RNA described above, a cell membrane-permeable peptide fragment (cell-penetrating peptide; hereinafter referred to as "CPP") that can introduce foreign substances into the cell from outside the cell through the cell membrane. The composition can be introduced into the cytoplasm and / or nucleus by CPP. By directly or indirectly binding (linking) CPP to the double-stranded RNA disclosed herein, a construct containing CPP and double-stranded RNA is constructed. Generally, double-stranded RNA has a negative charge and therefore does not easily pass through the cell membrane. However, for example, by directly or indirectly binding (linking) the double-stranded RNA disclosed herein to the N-terminal and / or C-terminal side of CPP, the construct containing CPP and double-stranded RNA can be efficiently introduced into the cell. The number of amino acid residues of CPP is not limited as long as its cell membrane permeability is not significantly impaired.
[0071] When CPP and double-stranded RNA are indirectly bound, a linker is positioned between them, for example. The type of linker is not particularly limited. Typically, it is a peptidic linker, a non-peptidic linker, etc. Furthermore, the method of binding CPP and double-stranded RNA is not particularly limited and can be carried out according to various conventionally known scientific methods.
[0072] One embodiment of the composition disclosed herein comprises CPP and the double-stranded RNA of this disclosure. However, the double-stranded RNA does not have to be bound to the N-terminal or C-terminal side of the CPP. For example, the double-stranded RNA and CPP may form a complex through electrical or molecular interactions. Such a complex is more readily introduced into eukaryotic cells, thus enabling efficient introduction of the double-stranded RNA. Nucleic acids such as double-stranded RNA are typically negatively charged. Therefore, the CPP used is preferably positively charged with a high proportion of basic amino acids. In this case, the proportion of CPP may be 5 to 100 times the amount of double-stranded RNA in molar terms, and preferably 40 to 60 times.
[0073] For CPPs, known ones can be used. For example, you can refer to van Asbeck et al., "Molecular Parameters of siRNA-Cell Penetrating Peptide Nanocomplexes for Efficient Cellular Delivery", ACS Nano., vol.7, No.5, pp. 3797-3807, 2013.
[0074] <Method of Use> This disclosure may provide a method for inhibiting the proliferation of at least one type of cell using the composition disclosed herein. The method disclosed herein includes a preparation step of preparing the composition disclosed herein and an administration step of administering the composition to cells in vitro or in vivo.
[0075] In the preparation step, for example, the composition disclosed herein can be prepared by conventionally known methods as described above.
[0076] In the administration step, the composition prepared in the preparation step is administered to at least one type of cell (e.g., tumor cells) in vivo or in vitro. Such cells may be, for example, eukaryotic cells. In this specification, "eukaryotic cells" in vivo includes, for example, various tissues, organs, tissues, blood, and lymph. In this specification, "eukaryotic cells" in vitro includes, for example, various cell aggregates, tissues, organs, tissues, tissues, blood, and lymph extracted from living organisms, as well as cell lines. The species of eukaryotic cells are not particularly limited and may include, for example, mammals, birds, amphibians, reptiles, fish, etc. The target cells may be, for example, cells expressing CDK5 mRNA having the same base sequence as the main sequence of the double-stranded RNA contained in the composition (e.g., human cells). In one example, such cells may be tumor cells (e.g., lung cancer cells). The cell types to which the composition is administered may be one or two or more.
[0077] The method of administering the composition may be in accordance with conventionally known methods and is not particularly limited. The composition may be used in vivo in a manner and in a dosage appropriate to its form and purpose. For example, as a liquid, it can be administered in any desired amount to the affected area (e.g., malignant tumor tissue, virus-infected tissue, inflamed tissue, etc.) of a patient or animal (i.e., a living organism) by injection intravenously, lymphatically, intramuscularly, subcutaneously, intradermally, or intraperitoneally. Alternatively, solid forms such as tablets, or gels or aqueous jelly forms such as ointments, can be administered directly to the designated tissue (e.g., the affected area, such as tissue or organ containing tumor cells, inflammatory cells, etc.). Alternatively, solid forms such as tablets can be administered orally. In the case of oral administration, encapsulation or application of a protective (coating) material is preferable to suppress digestive enzyme degradation in the gastrointestinal tract.
[0078] In vivo, the amount of composition administered is not particularly limited. For example, the amount of double-stranded RNA per kg of animal may be 0.01 mg or more, 0.05 mg or more, or 0.1 mg or more. Alternatively, the amount of double-stranded RNA per kg of animal may be, for example, 10 mg or less, 5 mg or less, 2 mg or less, or 1 mg or less.
[0079] In vitro, the amount of composition to be administered is not particularly limited. For example, the double-stranded RNA concentration in the culture medium of a target including cells may be 1 nM or more, 10 nM or more, or 50 nM or more. Alternatively, the double-stranded RNA concentration in such a culture medium may be, for example, 5 μM or less, 2 μM or less, 1 μM or less, or 500 nM or less.
[0080] The compositions disclosed herein can be introduced into target cells by known transfection methods. Examples include chemical gene transfer methods using cationic molecules (such as commercially available transfection reagents), physical transfer methods such as microinjection and electroporation, and biological gene transfer methods using viruses. Furthermore, as described above, they may be introduced into cells using CPP. The compositions disclosed herein may also contain substances (such as reagents) used in known transfection methods.
[0081] The following describes some test examples relating to the technology disclosed herein, but the technology disclosed herein is not intended to be limited to those shown in such test examples.
[0082] <Preparation of Double-Stranded RNA> Polynucleotides with the base sequences shown in SEQ ID NOs: 11-26 were artificially synthesized. The base sequences of each polynucleotide are shown in Table 1. The sense strands consisting of the base sequences shown in SEQ ID NOs: 11, 13, 15, 17, 19, 21, 23, and 25 each have the base sequences shown in SEQ ID NOs: 1-8 as their main sequence. In each polynucleotide, the "TT" (additional sequence) at the 3' end is DNA, and the other sequences (main sequence or complementary sequence) are composed of RNA. The obtained polynucleotides were used to prepare double-stranded RNAs of samples 1-8 shown in Table 1 by annealing the sense strand and antisense strand having complementary sequences. The double-stranded RNAs of samples 1-8 were each dissolved in sterile water (DNase and RNase-free) to a double-stranded RNA concentration of 200 μM to prepare RNA solutions.
[0083]
[0084] <Cell Proliferation Test> (Example 1) Human lung cancer cells, A549 cells, were used as eukaryotic cells. A549 cells were pre-cultured in the culture medium of 10% FBS (fetal bovine serum) + E-MEM (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., Cat No. 051-07615) + 1% MEM non-essential amino acid solution (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., Cat No. 139-15651). 0.5% penicillin-streptomycin (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., Cat No. 168-23191) was added to the culture medium only during pre-culture, but not during subsequent culture and evaluation.
[0085] First, as a pre-culture, A549 cells were cultured on a culture plate. After washing the A549 cells attached to the culture plate with PBS, a 0.25% trypsin / EDTA solution was added and incubated at 37°C for 2 minutes. After incubation, the above culture medium was added to inactivate the trypsin. Then, the cells were precipitated by centrifugation at 150 × g for 5 minutes. After removing the supernatant produced by centrifugation, the above culture medium was added to the precipitate (cell pellet) and approximately 2 × 10⁻⁶ cells were added. 4 A cell suspension was prepared at cells / mL. A commercially available 96-well plate was prepared, and the cell suspension was placed in each well at a rate of 2 × 10⁶. 3 Sow seeds at a density of cells / 100 μL / well, and maintain a temperature of 37°C and 5% CO2. 2 It was incubated overnight below.
[0086] Next, solution A was prepared by mixing 1 μL of RNA solution with a concentration of 200 μM of sample 1 with 25 μL of Opti-MEM (Thermo Fisher Scientific). Solution B was also prepared by mixing 1.5 μL of Lipofectamine RNAiMAX (Thermo Fisher Scientific) with 25 μL of Opti-MEM. Next, solution C was prepared by mixing equal volumes of solution A and solution B, and incubated at room temperature for 5 minutes. The prepared solution C was added to the wells containing cultured A549 cells, adjusting the concentration of sample 1 in the culture medium in the wells to 0.4 μM. Afterward, incubation was performed at 37°C and 5% CO2. 2 A549 cells were incubated for 72 hours below.
[0087] The cell volume in each well was evaluated using Cell Counting Kit-8 (CCK-8, Dojin Kagaku Kenkyusho). 10 μL of the CCK-8 reagent was added to each well containing A549 cells cultured on day 4 after the start of culture (day 3 after the addition of double-stranded RNA), and the cells were cultured at 37°C and 5% CO2. 2The cells were incubated for 1.5 hours under the following conditions. Afterward, the absorbance at 450 nm was measured for each well. The absorbance was the average of the three wells. A blank well containing only culture medium and CCK-8 reagent was also prepared. The value obtained by subtracting the absorbance of the blank well from the absorbance of Sample 1 was used as the measured value for Sample 1. The relative value for Example 1 was determined using the measured value of the reference example described later as the baseline. This relative value was used as the cell viability to determine the cell viability of Example 1.
[0088] (Examples 2-8) In Examples 2-8, cell viability was determined in the same manner as in Example 1, except that Sample 1 was replaced with Samples 2-8 respectively. Note that the sample numbers and example numbers correspond.
[0089] (Reference Example) In the reference example, the procedure was the same as in Example 1, except that sterile water was used instead of RNA solution. In other words, double-stranded RNA was not added in the reference example.
[0090] Figure 1 is a graph showing the cell viability of each example. The reference example is shown with a cell viability of 100%. As shown in Figure 1, the cell viability of Examples 1-8 was lower compared to the reference example. In particular, the cell viability of Examples 1-4 was especially low. Furthermore, the cell viability of Examples 1 and 3 was even more significantly lower. From this, it can be seen that double-stranded RNA having any of the base sequences of SEQ ID NOs: 1-8 as its main sequence exhibits function as double-stranded RNA that targets CDK5. In particular, it can be seen that double-stranded RNA having the base sequence shown in SEQ ID NOs: 1 or 3 as its main sequence can exhibit function as double-stranded RNA that targets CDK5 in a particularly significant way.
[0091] The specific examples of the technologies disclosed herein have been described in detail above, but these are merely illustrative and do not limit the scope of the claims. The technologies described in the claims include various modifications and changes to the specific examples described above.
[0092] Specific embodiments of the technology disclosed herein include those described in the following sections: Section 1: A double-stranded RNA comprising a first strand containing a main sequence and a second strand containing a complementary sequence that binds complementaryly to the main sequence, wherein the main sequence consists of any of the following base sequences: CAUUCCUCUUCCAGCUACU (Sequence ID 1); CCUCUUCCAGCUACUAAA (Sequence ID 2); GGGCUGGGAAUUCUGUCAUA (Sequence ID 3); and GGUCAGCCCGGCUGCAUCUU (Sequence ID 4); Item 2: The double-stranded RNA according to Item 1, wherein the first strand comprises a first additional sequence consisting of one to four nucleotides attached to the 5' end and / or 3' end of the main sequence, and the second strand comprises a second additional sequence consisting of one to four nucleotides attached to the 5' end and / or 3' end of the complementary sequence. Item 3: The double-stranded RNA according to Item 2, wherein the nucleotide sequence constituting the first additional sequence is thymine-thymine (TT). Item 4: The double-stranded RNA according to Item 2 or 3, wherein the nucleotide sequence constituting the second additional sequence is thymine-thymine (TT). Item 5: The double-stranded RNA according to any one of Items 2 to 4, wherein the first strand and / or the second strand contains nucleotide analogs. Item 6: A double-stranded RNA according to any one of Items 1 to 5, wherein the base sequence constituting the first strand is 19 to 27 bases, and the base sequence constituting the second strand is 19 to 27 bases. Item 7: A composition comprising the double-stranded RNA according to any one of Items 1 to 6. Item 8: A method for inhibiting the proliferation of at least one type of cell, comprising the steps of preparing the composition according to Item 7 and providing the composition to the cell.
Claims
1. A double-stranded RNA comprising a first strand containing a main sequence and a second strand containing a complementary sequence that binds complementaryly to the main sequence, wherein the main sequence consists of any of the following base sequences: CAUUCCUCUUCCAGCUACU (Sequence ID 1); CCUCUUCCAGCUACUAAA (Sequence ID 2); GGGCUGGGAAUUCUGUCAUA (Sequence ID 3); and GGUCAGCCCGGCUGCAUCUU (Sequence ID 4).
2. The double-stranded RNA according to claim 1, wherein the first strand includes a first addition sequence consisting of a nucleotide sequence of 1 to 4 nucleotides attached to the 5' end and / or 3' end of the main sequence, and the second strand includes a second addition sequence consisting of a nucleotide sequence of 1 to 4 nucleotides attached to the 5' end and / or 3' end of the complementary sequence.
3. The double-stranded RNA according to claim 2, wherein the base sequence constituting the first additional sequence is thymine-thymine (TT).
4. The double-stranded RNA according to claim 2, wherein the base sequence constituting the second additional sequence is thymine-thymine (TT).
5. The double-stranded RNA according to claim 2, wherein the first strand and / or the second strand comprises a nucleotide analog.
6. The double-stranded RNA according to claim 1, wherein the base sequence constituting the first strand is 19 bases or more and 27 bases or less, and the base sequence constituting the second strand is 19 bases or more and 27 bases or less.
7. A composition comprising the double-stranded RNA described in any one of claims 1 to 6.
8. A method for inhibiting the proliferation of at least one type of cell, comprising the steps of: preparing the composition described in claim 7; and providing the composition to the cell in vitro.
